Induction of NANOG expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation.
Induction of *NANOG* expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation

Xiaoling WANG, Ji WANG, Vera HUANG, Robert F. PLACE and Long-Cheng LI

Department of Urology, University of California San Francisco, San Francisco, CA 94158, U.S.A. and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, U.S.A.

RNAa (RNA activation) is a mechanism by which small dsRNA (double-stranded RNA), termed saRNA (small activating RNA), target promoter sequences to induce gene expression. This technique represents a novel approach to gene overexpression without the use of exogenous DNA. In the present study, we investigated whether RNAa can modulate expression of the development-related gene *NANOG* and manipulate cell fate. Using a lentivirus-based reporter system as a screening tool, we identified synthetic saRNAs that stimulate *NANOG* expression in human NCCIT embryonic carcinoma cells. Mismatch mutations to saRNA duplexes define sequence requirement for gene activation. Functional analysis of *NANOG* induction reveals saRNA treatment predictably modulates the expression of several known downstream target genes, including *FOXH1* (forkhead box H1), *REST* (RE1-silencing transcription factor), *OCT4* (octamer-binding protein 4) and *REX1* (reduced expression protein 1). Treatment with RA (retinoic acid) triggers NCCIT cell differentiation, reducing *NANOG* and *OCT4* expression and up-regulating several neural markers [i.e. ASCL1 (achaete-scute complex homologue 1), *NEUROD1* (neuronal differentiation 1) and *PAX6* (paired box 6)]. However, co-treatment with saRNA antagonizes *NANOG* down-regulation and RA-induced differentiation. Ectopic overexpression of *NANOG* via lentiviral transduction further recapitulates saRNA results, providing proof-of-concept that RNAa may be utilized to activate development-related genes and manipulate cell fate.

Key words: cell fate, differentiation, induced pluripotent stem cell (iPS cell), *NANOG*, RNA activation (RNAa).

**INTRODUCTION**

RNAa (RNA activation) is a newly identified phenomenon of gene induction triggered by small dsRNAs (double-stranded RNAs) [1–3]. This class of dsRNA, termed saRNA (small activating RNA), targets non-coding sequences in gene promoters leading to changes in chromatin structure and transcriptional activation [1,3–5]. RNAa is conserved in at least mammalian cells having been shown to activate a number of genes, including *CDKN1A* (cyclin-dependent kinase inhibitor 1A; p21), *CDH1* (E-cadherin), *PGR* (progesterone receptor), *KLF4* (Kruppel-like factor 4), *VEGF* (vascular endothelial growth factor), *NKX3.1* (NK3 homeobox 1), *TP53* (p53) etc. [2,6–8]. As such, saRNAs represent a novel tool for stimulating endogenous gene expression.

Viral-mediated overexpression systems are widely used to manipulate cell fate. For instance, ectopic expression of various defined factors [e.g. *OCT4* (octamer-binding protein 4), *GATA4* (GATA-binding protein 4)] has been used to generate iPS (induced pluripotent stem) cells and direct conversion of fibroblasts into blood progenitor cells or cardiomyocytes [9–11]. However, viral-based systems have inherent drawbacks that interfere with clinical application, including adverse effects on the host genome integrity and immunological consequences. Alternative approaches to gene overexpression that circumvent such problems may improve therapeutic development of cell-based technologies.

*NANOG* is a transcription factor that plays a critical role in regulating cell fate. In embryonic development, it is involved in maintaining the pluripotent ICM (inner cell mass), sustaining the epiblast and preventing cell differentiation [12–15]. *NANOG* is also highly expressed in pluripotent cell lines, including ES (embryonic stem), EG (embryonic germ) and EC (embryonic carcinoma) cells. However, *NANOG* levels sharply decline at the post-implantation stages of embryogenesis and during differentiation in cell culture [12]. In fact, suppression of *NANOG* alone can cause ES cells to differentiate into extra-embryonic lineages [16,17]. Ectopic expression of *NANOG* has also been utilized to maintain pluripotent phenotypes in cultured ES cells. For instance, *NANOG* overexpression has been reported to maintain mouse ES cell pluripotency in the absence of LIF (leukaemia inhibitory factor) [12], as well as to enable human ES cells to grow in a feeder-free environment [18]. *NANOG* is among the four defined stem cell factors used to reprogram human fibroblasts into iPS cells [19]. Although *NANOG* is dispensable in some instances of iPS reprogramming, it is a stringent selection marker for germline-competent iPS cells with increased ES cell-like properties [20]. Currently, almost all methods of *NANOG* overexpression require the use of exogenous genetic material (e.g. viral-based vectors). In the present study, we identify saRNAs that activate *NANOG* expression and antagonize RA (retinoic acid)-induced differentiation of NCCIT cells. Our results provide...
pros-of-concept that RNAa may provide an alternative approach to DNA-based overexpression systems for manipulating cell fate.

EXPERIMENTAL

saRNA design

A 1 kb section of the human NANOG promoter sequence was scanned for saRNA target sites based on rational design rules as reported previously [1,6]. All of the saRNA sequences found are listed in Supplementary Table S1 (available at http://www.BiochemJ.org/bj/443/bj4430821add.htm).

Cell culture and saRNA transfection

NCCIT cells were maintained in RPMI 1640 medium supplemented with 10% FBS (fetal bovine serum), 10 mM Hapes, 1 mM sodium pyruvate, 4.5 g/l glucose, 100 units/ml penicillin and 100 μg/ml streptomycin in a humidified atmosphere of 5% CO₂ maintained at 37 °C. Cells were plated in growth medium without antibiotics at a density of ~15%. Transfection of saRNAs was carried out using Lipofectamine™ RNAiMax (Invitrogen) according to the manufacturer’s instructions.

RA-induced differentiation

NCCIT cells were dissociated as single cells and maintained at the prescribed cell density in standard growth medium supplemented with 10 μM all-trans-RA (Sigma-Aldrich) for 2 weeks. RA was stored as a solution (10 mM in DMSO) and diluted in growth medium as needed. The medium was replenished every 2 days.

mRNA expression analysis

Total RNA was isolated by using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. RNA (1 μg) was reverse transcribed with oligo(dT) primers. The resulting cDNA samples were amplified by RT (reverse transcription)–PCR using gene-specific primer sets in conjunction with the Power SyBr Green PCR Master Mix (Applied Biosystems). All of the primer sequences are listed in Supplementary Table S1.

NANOG promoter reporter assay

The pGreen-Zeo-NANOG reporter plasmid was obtained from System Biosciences. It contained a 2587 bp fragment of the NANOG promoter (−2452/+135) cloned upstream of the destabilized GFP (green fluorescent protein) copGFP gene. Lentiviral particles were generated by transfecting HEK (human embryonic kidney)-293T cells (Invitrogen) with pGreen-Zeo-NANOG in conjunction with the packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen) for 48 h. The media were harvested and used to infect NCCIT cells. Puromycin (2 μg/ml) was used to select transduced cells 3 days after infection.

Lentivirus-based overexpression of NANOG

A lentiviral human NANOG cDNA overexpression vector (pSin-EF2-NANOG-Pur) was obtained from Addgene (Addgene plasmid 16578). Lentiviral particles were generated by transfecting HEK-293T cells (Invitrogen) with pSin-EF2-NANOG-Pur in conjunction with the packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen) for 48 h. The media were harvested and used to infect NCCIT cells. Puromycin (2 μg/ml) was used to select transduced cells 3 days after infection.

Immunoblot analysis

Immunoblot analysis was performed according to standard laboratory protocol as published previously [21,22]. Primary antibodies included anti-NANOG (1:1000 dilution; 3580S, Cell Signaling Technology), anti-β-3-tubulin (1:1000 dilution; ab18207, Abcam) and anti-OCT-3/4 (C-10) (1:1000 dilution, mouse monoclonal; sc-5279, Santa Cruz Biotechnology) antibodies. Anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (1:5000 dilution, rabbit monoclonal; #2118, Cell Signaling Technology), anti-β-actin (1:3000 dilution; AC-15, Sigma–Aldrich), anti-Hsp70 (heat-shock protein 70) (1:2000 dilution; Thermo Fisher Scientific) and anti-α-tubulin (1:5000 dilution; Sigma–Aldrich) antibodies were used as loading controls.

Cell proliferation assay

Cells were transfected with saRNA and re-seeded into 96-well plates the next day at a density of 5000 cells/well. Cell proliferation was measured 4 days later by using the CellTiter96 Aqueous one solution cell proliferation assay kit (Promega) containing MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reagent according to the manufacturer’s protocol.

RESULTS AND DISCUSSION

Identification of saRNAs that target the NANOG promoter by using a GFP reporter system

NANOG expression is silenced in most normal primary and cancer cells [12]. However, NCCIT (human embryonic carcinoma) cells are a developmentally pluripotent cell line that express high levels of stem cell markers, including OCT4, NANOG, SSEA (stage-specific embryonic antigen)-1, SSEA-3, SSEA-4, TRA-1-81 etc. [23]. NCCIT cells can also be influenced to differentiate into derivatives of all three embryonic germ layers (i.e. ectoderm, mesoderm and endoderm) and extra-embryonic cell lineages [23,24]. As such, NCCIT cells were selected to determine whether RNAa can be used to activate NANOG expression in vitro and influence cell fate.

Selecting saRNA target sites within gene promoters is largely a hit-or-miss process. Promoter sequence, chromatin structure, accessibility, overlapping non-coding transcripts etc. may all play a role in influencing transcription and susceptibility to RNAa [5,8]. In order to improve screening efficiency, we generated stable NCCIT (NCCIT NANOG–GFP) cells that contained GFP under control of the human NANOG promoter by lentiviral transduction. Measuring GFP intensity would serve as a readout for the
transcriptional activity of the \textit{NANOG} promoter. We designed a series of saRNAs that targeted the \textit{NANOG} promoter at sites ranging from \(-82\) to \(-988\) relative to the TSS (transcription start site) by following previously described design rules [6] (Figure 1A and Supplementary Table S1). Each duplex was named according to its target within the \textit{NANOG} promoter (i.e. dsNanog-82, dsNanog-153, dsNanog-194 etc.). A control saRNA (dsControl) was also synthesized that lacked significant homology with all known human sequences. Each saRNA was transfected into NCCIT NANOG–GFP cells and the GFP intensity was assessed by flow cytometry. Compared with the control treatments, dsNanog-82, -205, -752 and -926 caused at least a 2.7-fold increase in the percentage of the GFP-positive populations, whereas the other saRNAs did not significantly alter GFP expression (Figure 1B). To exclude the possibility that cytotoxic effects may be contributing to the increase in GFP signal, a MTS assay was conducted on the transfected cells (Figure 1C). We found that dsNanog-752 had minimal effects on cell proliferation, whereas dsNanog-82, -205 and -926 similarly inhibited cell growth (Figure 1C). As such, cytotoxic effects may account for the subtle increase in GFP signal in dsNanog-82 and dsNanog-205 transfected cells. However, GFP induction by dsNanog-752 and dsNanog-926, which caused the highest shift among all \textit{NANOG} dsRNAs (Figure 1B), may not
result entirely from cytotoxicity, but rather increases in GFP expression.

**saRNA-mediated induction of endogenous NANOG expression in NCCIT cells**

To further validate the screening results, we individually transfected each saRNA into NCCIT cells and evaluated endogenous NANOG expression by quantitative RT–PCR. Compared with the control transfections, dsNanog-752 and dsNanog-926 caused a 2.87- and 2.97-fold increase in NANOG mRNA levels respectively (Figure 2A). The remaining duplexes did not significantly induce NANOG expression. Collectively, analysis of NANOG expression following saRNA treatment correlated with the results from the GFP reporter assay.

Immunoblot analysis indicated dsNanog-752 and dsNanog-926 also increased NANOG protein levels in NCCIT cells (Figure 2B). Morphologically mock- and dsControl-treated cells remained healthy, whereas dsNanog-752-transfected cells formed compact ES-like colonies (Figure 2C). As found when using the MTS assay, dsNanog-926 caused visible cytotoxic effects as cells appeared considerably less dense compared with other treatments (Figures 2C and 1C). Potential off-target effects and/or stimulation of the innate immune response may contribute to the cytotoxicity of dsNanog-926 in NCCIT cells. As such, all subsequent experiments focused on dsNanog-752.

Analysis of mRNA expression also revealed NANOG was induced in a dose-dependent manner by dsNanog-752 at concentrations ranging from 10 to ∼50–100 nM, whereas concentrations higher than ∼50–100 nM did not further increase NANOG expression (Figure 2D). Time-course experiments revealed that NANOG protein levels were not induced until day 3–4, with peak activity around day 5 (Figure 2E). NANOG levels remained elevated up to day 12. Previous studies have shown RNAi possesses kinetics distinct from RNAa (RNA interference) as characterized by an initial ∼48 h delay with ∼10 day continuation in gene activation [1,2,25]. These unique features of RNAa have been attributed to its nuclear nature and consequent epigenetic changes at targeted promoters [1,8,25]. Our observations in the present study reveal that activation NANOG by dsNanog-752 follows the typical kinetics of RNAa.

**Sequence requirement of dsNanog-752 for RNAa induction**

To characterize the sequence requirement for dsNanog-752, we created several mutant saRNAs in which nucleotides at either the 5′-end (dsNanog-752-5′m-1 and dsNanog-752-5′m-2) or 3′-end (dsNanog-752-3′m-1 and dsNanog-52-3′m-2) relative with the antisense strand of dsNanog-752 possessed mismatches with the targeted promoter sequence (Figure 3A). Analysis of mRNA expression revealed that dsNanog-752-3′m-1 and dsNanog-752-3′m-2 possessed activity similar to wild-type dsNanog-752, whereas dsNanog-752-5′m-1 and dsNanog-752-5′m-2 were not capable of inducing NANOG expression (Figure 3B). Immunoblot analysis also confirmed mutant saRNA RT–PCR results (Figure 3C). These findings indicate that mutation to the 3′-end of dsNanog-752 does not interfere with RNAa activity, whereas mutation of the 5′-end abolishes its ability to activate NANOG expression. Similar to our previous results evaluating the sequence requirement for RNAa at the E-cadherin and p21 promoters [1,3], the 5′-end of the antisense strand in dsNanog-752 is important for RNAa specificity. As such, the
Using RNA activation to manipulate cell fate

Figure 3 Sequence requirement for dsNanog-752

(A) Mutations to the 5′-end (relative of the antisense strand) of dsNanog-752 resulted in duplexes dsNanog-752-5′-m-1 and dsNanog-752-5′-m-2. Mutations to the 3′-end of dsNanog-752 created mutant derivatives dsNanog-752-3′-m-1 and dsNanog-752-3′-m-2. The mutated bases are shown in bold. (B) NCCIT cells were transfected with 50 nM of the indicated saRNA molecules for 96 h. Expression of NANOG was accessed by quantitative RT–PCR and normalized to GAPDH. Results are fold changes relative to mock transfections (means ± S.D. for two independent experiments). *P < 0.05 compared with the mock. (C) NCCIT cells were transfected as in (B) and NANOG protein levels were detected by immunoblot analysis. α-Tubulin served as a loading control.

antisense strand likely serves as the ‘guide’ strand responsible for targeting sequence at the NANOG promoter.

NANOG induction by saRNA modulates the expression of its downstream genes

NANOG is a key transcription factor involved in regulating embryonic development and self-renewal of pluripotent stem cells. Using genome-wide location analyses, hundreds of genes have been identified as downstream targets of NANOG [26–28]. To determine if RNAa-based overexpression of NANOG influences downstream gene expression, we evaluated mRNA levels of several known downstream genes [i.e. OCT4, REX1 (reduced expression protein 1), REST (RE1-silencing transcription factor) and FOXH1 (forkhead box H1)] [29,30] following dsNanog-752 transfection in NCCIT cells. As a positive control, NANOG cDNA was also overexpressed in NCCIT cells using a lentiviral vector (pSin-Nanog). As expected, ectopic overexpression of pSin-Nanog elevated NANOG mRNA levels by 8.3-fold and predictably increased expression of all four downstream genes (Figure 4). Similarly, albeit to a lesser extent, dsNanog-752 also up-regulated the expression of each downstream gene (Figure 4). This result suggests restoration of endogenous NANOG expression by RNAa results in a functional protein capable of predictably modulating the expression of its downstream genes.

NANOG activation by saRNA antagonizes RA-induced differentiation in NCCIT cells

Since exogenous NANOG expression can sustain pluripotency in ES cells [12,18], it would be interesting to determine if RNAa-mediated overexpression of NANOG can also prevent cell differentiation. It has been reported that certain chemical compounds (e.g. RA) induce neuronal-like features in human embryonic carcinoma cells [23]. To analyse the effects of dsNanog-752 on RA-induced differentiation, we treated NCCIT cells with 10 μM RA for 2 weeks. During this period, the cells were transfected with dsNanog-752 every 4 days for a total of 12 days. NCCIT cells transfected with pSin-Nanog lentivirus particles were also treated with RA and served as a positive control.
Figure 5  dsNanog-752 maintains an ES-like morphology in NCCIT cells treated with RA

NCCIT cells treated with 10 μM RA were transfected with 50 nM of the indicated dsRNAs every 4 days. Representative phase-contrast cell images were taken at 40× magnification on day 14 after transfection.

Figure 6  dsNanog-752 antagonizes RA-induced differentiation in NCCIT cells

NCCIT cells were cultured with 10 μM RA and co-treated with 50 nM concentrations of the indicated saRNAs every 96 h for 14 days. NCCIT cells transduced with lentivirus (pSin-Nanog) served as a positive control for NANOG overexpression. mRNA expression levels of NANOG (A) and OCT4 (B) were assessed by quantitative RT–PCR and normalized to that of GAPDH. Results are fold changes relative to the 10 μM RA treatment (means ± S.D. for three independent experiments). (C) Protein levels of OCT4 were detected by immunoblot analysis. GAPDH served as a loading control. Representative blot of n = 2. (D) Neural markers ASCL1, NEUROD1 and PAX6 were assessed by quantitative RT–PCR and normalized to that of GAPDH. Results are fold changes relative to the 10 μM RA treatment (means ± S.D. for three independent experiments). * P < 0.05 compared with RA. ND, not detectable. (E) Protein levels of β-3-tubulin were detected by immunoblot analysis. β-actin served as a loading control. Representative blot of n = 2.
control for NANOG overexpression. Phenotypically, RA forced mock- and dsControl-treated cells to differentiate as evident by the loss of compact, ES-like colony structure, whereas dsNanog-752 and lentiviral Nanog overexpression allowed cells to retain ES-like colony morphology (Figure 5). Expression analysis by quantitative RT–PCR revealed RA also caused a 98.7% decrease in NANOG mRNA levels compared with the untreated cells; however, dsNanog-752 sustained NANOG expression in the presence of RA treatment resulting in ∼15.7-fold higher NANOG mRNA levels compared with dsControl transfected cells (Figure 6A). Lentiviral transduced cells (pSin-Nanog) produced ∼1500-fold higher NANOG mRNA levels compared with dsControl treatments (Figure 6A). Since OCT4 is a key downstream gene of NANOG, we also evaluated its expression following RA-induced differentiation in NCCIT cells. As shown in Figures 6(B) and 6(C), expression of OCT4 exhibited a pattern in concordance with NANOG (Figure 6A), suggesting tight regulation of OCT4 by NANOG in NCCIT cells. Interestingly, despite differences in magnitude between RNAa- and lentiviral-mediated overexpression of NANOG in RA-treated cells (Figure 6A), both techniques maintained similar levels of OCT4 expression (Figure 6B). It has been proposed that RNAa may represent a more natural approach to gene overexpression capable of facilitating similar measurable effects on downstream phenotypes as ectopic overexpression systems without the need for massive product output [6].

Consistent with the findings from previous studies [23,31], RA treatment also up-regulated several markers for neural differentiation [i.e. ASCL1 (achaete-scute complex homologue 1), NEUROD1 (neuronal differentiation 1) and PAX6 (paired box 6)], suggesting RA promotes differentiation of NCCIT cells towards neurons (Figure 6D). However, co-treatment with dsNanog-752 significantly curbed neural marker gene up-regulation by RA in a manner similar to pSin-Nanog-transduced cells (Figure 6D). Although not sufficient to completely halt RA activity, these results demonstrate that dsNanog-752 antagonized the differentiation phenotype induced by RA treatment in NCCIT cells. In support of this, immunoblot analysis revealed dsNanog-752 also decreased expression of neural differentiation marker β-3-tubulin (Figure 6E).

Taken together, this study utilizes RNAAs as a molecular tool to enhance expression of NANOG in human NCCIT cells. NANOG overexpression by dsNanog-752 led to the predictable modulation of several downstream genes and antagonized RA-induced differentiation. Furthermore, these results were recapitulated by vector-mediated overexpression of NANOG. The findings of the present study provide proof-of-concept that RNAAs may provide an alternative approach to DNA-based overexpression systems for manipulating cell fate and activating development-related genes.

**AUTHOR CONTRIBUTION**

Long-Cheng Li and Xiaoling Wang conceived the study, designed the experiments, analysed the data and wrote the paper. Xiaoling Wang and Ji Wang performed the experiments. Vera Huang and Robert Place contributed to the experimental design and wrote the paper.

**FUNDING**

This work was supported by the California Institute for Regenerative Medicine [grant number RL1-00660-1] and the National Institutes of Health [grant number 1R01GM09293-01].

**REFERENCES**

1. Li, L. C., Okino, S. T., Zhao, H., Pookot, D., Place, R. F., Urakami, S., Enokida, H. and Daihya, R. (2000) Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. U.S.A. 103, 17337–17342

2. Janowski, B. A., Younger, S. T., Hardy, D. B., Ram, R., Huffman, K. E. and Corey, D. R. (2007) Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3, 166–173

3. Place, R. F., Li, L. C., Pookot, D., Noorinan, E. J. and Daihya, R. (2008) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U.S.A. 105, 1665–1613

4. Morris, K. V., Santoso, S., Turner, A. M., Pastori, C. and Hawkins, P. G. (2008) Bidirectional transcription directly both transcriptional gene activation and suppression in human cells. PLoS Genet. 4, e1000258

5. Schwartz, J. C., Younger, S. T., Nguyen, N. B., Hardy, D. B., Monia, B. P., Corey, D. R. and Janowski, B. A. (2008) Antisense transcripts are targets for activating small RNAs. Nat. Struct. Mol. Biol. 15, 842–848

6. Huang, V., Qin, Y., Wang, J., Wang, X., Place, R. F., Lin, G., Liu, T. F. and Li, L. C. (2010) RNAa is conserved in mammalian cells. PLoS ONE 5, e8848

7. Chu, Y., Yue, X., Younger, S. T., Janowski, B. A. and Corey, D. R. (2010) Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res. 38, 7736–7748

8. Portnoy, V., Huang, V., Place, R. F. and Li, L. C. (2011) Small RNA and transcriptional upregulation. Wiley Interdiscip. Rev.: RNA 2, 748–760

9. Ieda, M., Fu, J. D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B. G. and Srivastava, D. (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142, 375–386

10. Grabo, E., Rampalli, S., Risaeno, R. M., Schnerr, A., Mitchell, R., Fiebig-Cony, A., Levadoux-Martin, M. and Bhaila, M. (2010) Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 468, 521–526

11. Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kobukov, Y., Sudhof, T. C. and Wernig, M. (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035–1041

12. Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S. and Smith, A. (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113, 643–655

13. Mitsui, K., Tokuzawa, Y., Itah, H., Sogawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M. and Yamanaka, S. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113, 631–642

14. Chambers, I., Silva, J., Colby, D., Nichols, J., Nijmeijer, B., Robertson, M., Vrana, J., Jones, K., Groteveld, L. and Smith, A. (2007) Nanog safeguards pluripotency and mediates germline development. Nature 450, 1230–1234

15. Silva, J., Nichols, J., Theunissen, T. W., Goo, G., van Oostrum, A. L., Barrandon, O., Wray, J., Yamanaka, S., Chambers, I. and Smith, A. (2005) Nanog is the gateway to the pluripotent ground state. Cell 138, 722–737

16. Hamazaki, T., Kehoe, S. M., Nakano, T. and Terada, N. (2006) The G0/G1/Meck pathway represses Nanog in murine embryonic stem cells. Mol. Cell. Biol. 26, 7539–7549

17. Hyslop, L., Stojkovic, M., Armstrong, L., Walter, T., Stojkovic, P., Przyborski, S., Herbert, M., Murdoch, A., Strachan, T. and Lako, M. (2005) Downregulation of Nanog induces differentiation of human embryonic stem cells to extraembryonic lineages. Stem Cells 23, 1035–1043

18. Dar, H., Mayshar, Y. and Benvenisty, N. (2006) Overexpression of NANOG in human ES cells enables feeder-free growth while inducing primitive ectoderm features. Development 133, 1193–1201

19. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R. et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920

20. Okita, K., Ichisaka, T. and Yamanaka, S. (2007) Generation of germ-line-competent induced pluripotent stem cells. Nature 448, 313–317

21. Noonan, E. J., Place, R. F., Basak, S., Pookot, D. and Li, L. C. (2010) miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 1, 349–358

22. Huang, V., Place, R. F., Portnoy, V., Wang, J., Qi, Z., Jia, Z., Yu, A., Shuman, M., Yu, J. and Li, L. C. (2012) Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 40, 1695–1707

23. Damjanovic, I., Horvat, B. and Gibas, Z. (1993) Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab. Invest. 68, 220–232

24. Jung, K. H., Das, N. D., Park, J. H., Lee, H. T., Choi, M. R., Chung, M. K., Park, K. S., Jung, M. H., Lee, B. C., Choi, I. G. and Choi, Y. G. (2010) Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol. In Vitro 24, 1696–1704
X. Wang and others

25 Place, R. F., Noonan, E. J., Foldes-Papp, Z. and Li, L. C. (2010) Defining features and exploring chemical modifications to manipulate RNAa activity. Curr. Pharm. Biotechnol. 11, 518–526

26 Sharov, A. A., Masui, S., Sharova, L. V., Piao, Y., Aiba, K., Matoba, R., Xin, L., Niwa, H. and Ko, M. S. (2008) Identification of Pou5f1, Sox2, and Nanog downstream target genes with statistical confidence by applying a novel algorithm to time course microarray and genome-wide chromatin immunoprecipitation data. BMC Genomics 9, 269

27 Loh, Y. H., Wu, Q., Chew, J. L., Vega, V. B., Zhang, W., Chen, X., Bourque, G., George, J., Leong, B., Liu, J. et al. (2006) The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 38, 431–440

28 Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G. et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947–956

29 Shi, W., Wang, H., Pan, G., Geng, Y., Guo, Y. and Pei, D. (2006) Regulation of the pluripotency marker Rex-1 by Nanog and Sox2. J. Biol. Chem. 281, 23319–23325

30 Pan, G., Li, J., Zhou, Y., Zheng, H. and Pei, D. (2006) A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. FASEB J. 20, 1730–1732

31 Tonge, P. D. and Andrews, P. W. (2010) Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner. Differentiation 80, 20–30

Received 15 August 2011/6 February 2012; accepted 17 February 2012
Published as BJ Immediate Publication 17 February 2012, doi:10.1042/BJ20111491
SUPPLEMENTARY ONLINE DATA

Induction of NANOG expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation

Xiaoling WANG, Ji WANG, Vera HUANG, Robert F. PLACE and Long-Cheng LI

Department of Urology, University of California San Francisco, San Francisco, CA 94158, U.S.A. and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, U.S.A.

Table S1 Sequences of dsRNA and oligonucleotide primers

The number in the dsRNA name denotes target location relative to the TSS.

(a)

| dsRNA name | Sequence (5′ → 3′) |
|------------|-------------------|
| dsNanog-82 | Sense, GGUGAAGGCCUCUAUU[dT][dT]  |
|            | Antisense, UAAUGAAGGCCUCUAUU[dT][dT] |
| dsNanog-153| Sense, AGACGGAUACUACUGAA[dT][dT]   |
|            | Antisense, UCUUGAUUAAUUCGUCU[dT][dT] |
| dsNanog-194| Sense, UGACGCUACUUUUGUAUUU[dT][dT] |
|            | Antisense, UAAUGAAGGCCUCUCUAA[dT][dT] |
| dsNanog-205| Sense, CUGGUUACUCUCAGCA[dT][dT] |
|            | Antisense, UAGCGUCAGAGUAACCC[dT][dT] |
| dsNanog-302| Sense, CCUGAUUAAAGGUUGAA[dT][dT] |
|            | Antisense, UUCACUUUAAAUUCGAG[dT][dT] |
| dsNanog-325| Sense, UCCGCUUUCGUACCA[dT][dT] |
|            | Antisense, UGGUGUACACAGGGAA[dT][dT] |
| dsNanog-752| Sense, GCCAGAUUUUGAGACACUA[dT][dT] |
|            | Antisense, UUGGUGUACCAAGGAA[dT][dT] |
| dsNanog-926| Sense, GGGAUAGACAAGAAACCAA[dT][dT] |
|            | Antisense, UUGGUUUCUUGUCUAUCCC[dT][dT] |
| dsNanog-988| Sense, CAGACCUGGGAAGAAGCA[dT][dT] |
|            | Antisense, UAGCGUGUGUGAGAGCAG[dT][dT] |
| dsControl  | Sense, ACUACUGAGAGUAGA[dT][dT] |
|            | Antisense, UCUACUGUCACUACUGAG[dT][dT] |

(b)

| Primer name | Sequence (5′ → 3′) |
|-------------|-------------------|
| NANOG       | Forward, AAAGAATCTCCTACCTATGCC |
|             | Reverse, GAAGGAAGAGGAGAGAGCT |
| FOXH1       | Forward, ACCTGCGACATGACAAGCC |
|             | Reverse, CTTTCCAGCCCTCGGAGCTT |
| REST        | Forward, GCATAAAGATCTGTGTAGGCAGG |
|             | Reverse, TCCTACTTGGAAAGGCGTGGACCA |
| OCT4        | Forward, GACGGGGAGGAGGAGGAGCTAGG |
|             | Reverse, CTTCCCACCAAGGAGGGGAAAC |
| REX1        | Forward, AAGGGGCAAAGCAAGACAC |
|             | Reverse, GCTGACATGAGCTAGTTCG |
| ASCL1       | Forward, CCTTGCTGAGATGGGACCTT |
|             | Reverse, TCGAGGTCCTGAGGCTTCTCC |
| NEUROD1     | Forward, GAAGGAAGAGGAGGAGATGAG |
|             | Reverse, TGGGTGGTGTTGGGATAAG |
| PAX6        | Forward, ACCCATCCAGAGATGTGTTGGCAG |
|             | Reverse, ATGGTGAGCTGGCGATGAGCAG |
| GAPDH       | Forward, ATCCACCTCCAGAGGAGCA |
|             | Reverse, TTGCTGAGSTTGGTGAACAG |

Received 15 August 2011/6 February 2012; accepted 17 February 2012
Published as BJ Immediate Publication 17 February 2012, doi:10.1042/BJ20111491

1 To whom correspondence should be addressed (email lilc@urology.ucsf.edu).

© 2012 The Author(s)

The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.